SCHEMBL732725

SCHEMBL732725

COc1ccc(C(=O)O)c(C)c1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.61
TDP1 Q9NUW8 2/20 0.61
ALDH1A1 P00352 4/20 0.52
MYC P01106 1/20 0.50
CDC25B P30305 1/20 0.49
KDM4E B2RXH2 5/20 0.47
HTT P42858 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HPGD P15428 2/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
TPMT P51580 1/20 0.47
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4309406 0.88 MAPT (0.62) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL30466426 0.88 MAPT (0.68) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL2425023 0.88 MAPT (0.68) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL11427275 0.85 MAPT (0.48) MAPTTDP1ALDH1A1CDC25BKDM4E
SCHEMBL57368 0.84 MAPT (0.62) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL20187687 0.84 MAPT (0.53) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL4143348 0.84 MAPT (0.68) MAPTTDP1ALDH1A1MYCKDM4E
SCHEMBL31335961 0.84 MAPT (0.62) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL27822908 0.84 CA12 (0.57) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL4779654 0.83 LMNA (0.51) MAPTTDP1ALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720038-A1 (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES Neophore Limited (GB) 2026-04-08 EP disclosed
US-12486258-B2 Compounds and methods for regulating insulin secretion THE BROAD INSTITUTE, INC. (US) 2025-12-02 US disclosed
WO-2024246496-A1 (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES Neophore Limited (GB) 2024-12-05 WO disclosed
US-20230142508-A1 COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION THE BROAD INSTITUTE, INC. (US) 2023-05-11 US disclosed
US-20230142508-A1 COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION THE BROAD INSTITUTE, INC. (US) 2023-05-11 US disclosed
US-20230142508-A1 COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION THE BROAD INSTITUTE, INC. (US) 2023-05-11 US disclosed
US-11555031-B2 Compounds and methods for regulating insulin secretion THE BROAD INSTITUTE, INC. (US) 2023-01-17 US disclosed
US-11203659-B2 Method for producing polyurethane, epoxy carboxylate composition, polyurethane, and polyurethane resin composition SHOWA DENKO K. K. (JP) 2021-12-21 US disclosed
WO-2021224818-A1 ISOINDOLONE COMPOUNDS AS HPK1 INHIBITORS PFIZER INC. (US) 2021-11-11 WO disclosed
US-20210221938-A1 METHOD FOR PRODUCING POLYURETHANE, EPOXY CARBOXYLATE COMPOSITION, POLYURETHANE, AND POLYURETHANE RESIN COMPOSITION SHOWA DENKO K. K. (JP) 2021-07-22 US disclosed
US-7601712-B2 Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists ONO PHARMACEUTICAL CO., LTD. (JP) 2009-10-13 US disclosed
WO-2009103484-A1 SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS MERCK PATENT GMBH (DE) 2009-08-27 WO disclosed
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-04 US disclosed
EP-1666473-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed
EP-1126833-A4 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES INC (US) 2004-09-08 EP disclosed
EP-1317241-A2 SHAMPOO COMPOSITIONS WITH CATIONIC POLYMERS THE PROCTER & GAMBLE COMPANY (US) 2003-06-11 EP disclosed
WO-2002022091-A2 SHAMPOO COMPOSITIONS WITH CATIONIC POLYMERS PROCTER & GAMBLE COMPANY (US) 2002-03-21 WO disclosed
US-20020012646-A1 Shampoo compositions with cationic polymers PROCTER & GAMBLE COMPANY, THE 2002-01-31 US disclosed
EP-1126833-A2 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2001-08-29 EP disclosed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142508-A1 COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION IAPP, GPR119, PNLIP MAPT 4653/4885TDP1 4637/4885ALDH1A1 4536/4885
US-11555031-B2 Compounds and methods for regulating insulin secretion IAPP, GPR119, INSR MAPT 4534/4885TDP1 4702/4885ALDH1A1 3610/4885
US-12486258-B2 Compounds and methods for regulating insulin secretion IAPP, GPR119, PNLIP MAPT 4653/4885TDP1 4637/4885ALDH1A1 4536/4885
US-20020012646-A1 Shampoo compositions with cationic polymers S100P, PSAP, PHOSPHO1 MAPT 3455/4885TDP1 4201/4885ALDH1A1 4384/4885
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient GPR17, CYSLTR1, KIT MAPT 1750/4885TDP1 4293/4885ALDH1A1 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.